Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Thyroid Disorders and Peripheral Arterial Disease

Author(s): Katica Bajuk Studen*, Simona Gaberscek, Katja Zaletel, Ales Blinc, Miso Sabovic, Gerit-Holger Schernthaner, Panagiotis Anagnostis, Pier Luigi Antignani, Mojca Jensterle, Dimitri P Mikhailidis and Pavel Poredos

Volume 22, Issue 1, 2024

Published on: 10 November, 2023

Page: [36 - 40] Pages: 5

DOI: 10.2174/0115701611271284231105063148

Price: $65

Abstract

Hypothyroidism and hyperthyroidism, both overt and subclinical, are associated with increased risk of cardiovascular morbidity and mortality. The association between thyroid-stimulating hormone levels and cardiovascular risk has been demonstrated in large epidemiological studies and meta-analyses and is now considered a U-shaped curve. Several pathophysiological mechanisms linking thyroid and cardiovascular disease are known; however, specific clinical complications of peripheral arterial disease as endpoints of clinical trials have not been adequately investigated. The potential mechanisms linking hypothyroidism and peripheral arterial disease are endothelial dysfunction, blood pressure changes, dyslipidemia, and low-grade systemic inflammation. The potential mechanisms linking hyperthyroidism and peripheral arterial disease are hyperdynamic circulation, elevated systolic blood pressure, hypercoagulability, and possibly increased arterial inflammation.

« Previous Next »
Graphical Abstract

[1]
Razvi S, Jabbar A, Pingitore A, et al. Thyroid hormones and cardiovascular function and diseases. J Am Coll Cardiol 2018; 71(16): 1781-96.
[http://dx.doi.org/10.1016/j.jacc.2018.02.045] [PMID: 29673469]
[2]
Müller P, Leow MKS, Dietrich JW. Minor perturbations of thyroid homeostasis and major cardiovascular endpoints—Physiological mechanisms and clinical evidence. Front Cardiovasc Med 2022.
[3]
Bernardi S, Grillo A, Antonello RM, et al. Meta-analysis on the association between thyroid hormone disorders and arterial stiffness. J Endocr Soc 2022; 6(4): bvac016.
[http://dx.doi.org/10.1210/jendso/bvac016] [PMID: 35284772]
[4]
Mizuma H, Murakami M, Mori M. Thyroid hormone activation in human vascular smooth muscle cells: expression of type II iodothyronine deiodinase. Circ Res 2001; 88(3): 313-8.
[http://dx.doi.org/10.1161/01.RES.88.3.313] [PMID: 11179199]
[5]
Hiroi Y, Kim HH, Ying H, et al. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci 2006; 103(38): 14104-9.
[http://dx.doi.org/10.1073/pnas.0601600103] [PMID: 16966610]
[6]
Davis PJ, Mousa SA, Lin HY. Nongenomic actions of thyroid hormone: The integrin component. Physiol Rev 2021; 101(1): 319-52.
[http://dx.doi.org/10.1152/physrev.00038.2019] [PMID: 32584192]
[7]
Shargorodsky M, Serov S, Gavish D, Leibovitz E, Harpaz D, Zimlichman R. Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma. Thyroid 2006; 16(4): 381-6.
[http://dx.doi.org/10.1089/thy.2006.16.381] [PMID: 16646685]
[8]
Duntas LH, Brenta G. A renewed focus on the association between thyroid hormones and lipid metabolism. Front Endocrinol 2018; 511.
[http://dx.doi.org/10.3389/fendo.2018.00511]
[9]
Selmer C, Olesen JB, Hansen ML, et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: A large population study. J Clin Endocrinol Metab 2014; 99(7): 2372-82.
[http://dx.doi.org/10.1210/jc.2013-4184] [PMID: 24654753]
[10]
Brandt F, Green A, Hegedüs L, Brix TH. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol 2011; 165(4): 491-7.
[http://dx.doi.org/10.1530/EJE-11-0299] [PMID: 21724839]
[11]
Ning Y, Cheng YJ, Liu LJ, et al. What is the association of hypothyroidism with risks of cardiovascular events and mortality? A meta-analysis of 55 cohort studies involving 1,898,314 participants. BMC Med 2017; 15(1): 21.
[http://dx.doi.org/10.1186/s12916-017-0777-9] [PMID: 28148249]
[12]
Lillevang-Johansen M, Abrahamsen B, Jørgensen HL, Brix TH, Hegedüs L. Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk. Eur J Endocrinol 2019; 180(6): 407-16.
[http://dx.doi.org/10.1530/EJE-19-0006] [PMID: 31035256]
[13]
Mazzeffi M, Lin HM, Flynn BC, O’Connell TL, DeLaet DE. Hypothyroidism and the risk of lower extremity arterial disease. Vasc Health Risk Manag 2010; 6(1): 957-62.
[http://dx.doi.org/10.2147/VHRM.S13535] [PMID: 21057580]
[14]
Mya MM, Aronow WS. Increased prevalence of peripheral arterial disease in older men and women with subclinical hypothyroidism. J Gerontol A Biol Sci Med Sci 2003; 58(1): M68-9.
[http://dx.doi.org/10.1093/gerona/58.1.M68] [PMID: 12560414]
[15]
Fang H, Zhao R, Cui S, Wan W. Sex differences in major cardiovascular outcomes and fractures in patients with subclinical thyroid dysfunction: a systematic review and meta-analysis. Aging (Albany NY) 2022; 14(20): 8448-85.
[http://dx.doi.org/10.18632/aging.204352] [PMID: 36287183]
[16]
Owen PJD, Sabit R, Lazarus JH. Thyroid disease and vascular function. Thyroid 2007; 17(6): 519-24.
[http://dx.doi.org/10.1089/thy.2007.0051] [PMID: 17614771]
[17]
Lekakis J, Papamichael C, Alevizaki M, et al. Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid 1997; 7(3): 411-4.
[http://dx.doi.org/10.1089/thy.1997.7.411] [PMID: 9226212]
[18]
Papadopoulou AM, Bakogiannis N, Skrapari I, Moris D, Bakoyiannis C. Thyroid dysfunction and atherosclerosis: A systematic review. In Vivo 2020; 34(6): 3127-36.
[http://dx.doi.org/10.21873/invivo.12147] [PMID: 33144416]
[19]
Koren Peleg R, Efrati S, Benbassat C, Fygenzo M, Golik A. The effect of levothyroxine on arterial stiffness and lipid profile in patients with subclinical hypothyroidism. Thyroid 2008; 18(8): 825-30.
[http://dx.doi.org/10.1089/thy.2007.0359] [PMID: 18651824]
[20]
Owen PJD, Rajiv C, Vinereanu D, Mathew T, Fraser AG, Lazarus JH. Subclinical hypothyroidism, arterial stiffness, and myocardial reserve. J Clin Endocrinol Metab 2006; 91(6): 2126-32.
[http://dx.doi.org/10.1210/jc.2005-2108] [PMID: 16537677]
[21]
Obuobie K, Smith J, Evans LM, John R, Davies JS, Lazarus JH. Increased central arterial stiffness in hypothyroidism. J Clin Endocrinol Metab 2002; 87(10): 4662-6.
[http://dx.doi.org/10.1210/jc.2002-020493] [PMID: 12364455]
[22]
Hamano K, Inoue M. Increased risk for atherosclerosis estimated by pulse wave velocity in hypothyroidism and its reversal with appropriate thyroxine treatment. Endocr J 2005; 52(1): 95-101.
[http://dx.doi.org/10.1507/endocrj.52.95] [PMID: 15758564]
[23]
Nagasaki T, Inaba M, Yamada S, et al. Decrease of brachial-ankle pulse wave velocity in female subclinical hypothyroid patients during normalization of thyroid function: A double-blind, placebo-controlled study. Eur J Endocrinol 2009; 160(3): 409-15.
[http://dx.doi.org/10.1530/EJE-08-0742] [PMID: 19114542]
[24]
Dernellis J, Panaretou M. Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism. Am Heart J 2002; 143(4): 718-24.
[http://dx.doi.org/10.1067/mhj.2002.120766] [PMID: 11923811]
[25]
Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003; 88(6): 2438-44.
[http://dx.doi.org/10.1210/jc.2003-030398] [PMID: 12788839]
[26]
Stabouli S, Papakatsika S, Kotsis V. Hypothyroidism and hypertension. Expert Rev Cardiovasc Ther 2010; 8(11): 1559-65.
[http://dx.doi.org/10.1586/erc.10.141] [PMID: 21090931]
[27]
Fommei E, Iervasi G. The role of thyroid hormone in blood pressure homeostasis: Evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab 2002; 87(5): 1996-2000.
[http://dx.doi.org/10.1210/jcem.87.5.8464] [PMID: 11994331]
[28]
Luboshitzky R, Aviv A, Herer P, Lavie L. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2002; 12(5): 421-5.
[http://dx.doi.org/10.1089/105072502760043512] [PMID: 12097204]
[29]
Duntas LH. Thyroid disease and lipids. Thyroid 2002; 12(4): 287-93.
[http://dx.doi.org/10.1089/10507250252949405] [PMID: 12034052]
[30]
Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160(4): 526-34.
[http://dx.doi.org/10.1001/archinte.160.4.526] [PMID: 10695693]
[31]
Diekman T, Demacker PNM, Kastelein JJP, Stalenhoef AFH, Wiersinga WM. Increased oxidizability of low-density lipoproteins in hypothyroidism. J Clin Endocrinol Metab 1998; 83(5): 1752-5.
[http://dx.doi.org/10.1210/jcem.83.5.4759] [PMID: 9589687]
[32]
Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000; 10(9): 803-8.
[http://dx.doi.org/10.1089/thy.2000.10.803] [PMID: 11041458]
[33]
Villar HCCE, Saconato H, Valente O, Atallah AN. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst Rev 2007; (3): CD003419.
[http://dx.doi.org/10.1002/14651858.CD003419.pub2]
[34]
Bansal SK, Suri A, Suryan V, Singh NK, Barman S. Level of non-conventional lipid parameters and its comparative analysis with TSH in subclinical hypothyroidism. Horm Mol Biol Clin Investig 2023; 44(1): 61-5.
[http://dx.doi.org/10.1515/hmbci-2022-0019] [PMID: 36049016]
[35]
Tan M, Korkmaz H, Aydin H, Kumbul Doğuç D. FABP4 levels in hypothyroidism and its relationship with subclinical atherosclerosis. Turk J Med Sci 2019; 49(5): 1490-7.
[http://dx.doi.org/10.3906/sag-1904-41] [PMID: 31651119]
[36]
Marfella R, Ferraraccio F, Rizzo MR, et al. Innate immune activity in plaque of patients with untreated and L-thyroxine-treated subclinical hypothyroidism. J Clin Endocrinol Metab 2011; 96(4): 1015-20.
[http://dx.doi.org/10.1210/jc.2010-1382] [PMID: 21239513]
[37]
Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab 2001; 86(2): 732-7.
[http://dx.doi.org/10.1210/jcem.86.2.7221] [PMID: 11158038]
[38]
Sohn SY, Lee E, Lee MK, Lee JH. The association of overt and subclinical hyperthyroidism with the risk of cardiovascular events and cardiovascular mortality: meta-analysis and systematic review of cohort studies. Endocrinol Metab 2020; 35(4): 786-800.
[http://dx.doi.org/10.3803/EnM.2020.728] [PMID: 33238332]
[39]
Lillevang-Johansen M, Abrahamsen B, Jørgensen HL, Brix TH, Hegedüs L. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk. Thyroid 2019; 29(3): 332-40.
[http://dx.doi.org/10.1089/thy.2018.0320] [PMID: 30648498]
[40]
Liu X, Wong CKH, Chan WWL, et al. Attaining biochemical euthyroidism early after total thyroidectomy in Graves’ disease may lower long-term morbidity risk. BJS Open 2022; 6(4): zrac079.
[http://dx.doi.org/10.1093/bjsopen/zrac079] [PMID: 35822337]
[41]
Danzi S, Klein I. Thyroid hormone and blood pressure regulation. Curr Hypertens Rep 2003; 5(6): 513-20.
[http://dx.doi.org/10.1007/s11906-003-0060-7] [PMID: 14594573]
[42]
Völzke H, Ittermann T, Schmidt CO, et al. Subclinical hyperthyroidism and blood pressure in a population-based prospective cohort study. Eur J Endocrinol 2009; 161(4): 615-21.
[http://dx.doi.org/10.1530/EJE-09-0376] [PMID: 19581285]
[43]
Grove-Laugesen Di, Malmstroem S, Ebbehoj E. Arterial stiffness and blood pressure in patients newly diagnosed with graves’ disease compared with euthyroid controls. Eur Thyroid J 2020; 9(3): 148-56.
[44]
Napoli R, Biondi B, Guardasole V, et al. Impact of hyperthyroidism and its correction on vascular reactivity in humans. Circulation 2001; 104(25): 3076-80.
[http://dx.doi.org/10.1161/hc5001.100621] [PMID: 11748103]
[45]
McAllister RM, Grossenburg VD, Delp MD, Laughlin MH. Effects of hyperthyroidism on vascular contractile and relaxation responses. Am J Physiol 1998; 274(5): E946-53.
[PMID: 9612254]
[46]
Yildiz C, Altay M, Yildiz S, et al. Arterial stiffness in hyperthyroid patients is deteriorated due to thyroid hormones. Arch Endocrinol Metab 2019; 63(3): 258-64.
[http://dx.doi.org/10.20945/2359-3997000000135] [PMID: 31066760]
[47]
Li YH, Lee IT. Hyperthyroidism and vascular cell adhesion molecule-1 are associated with a low ankle-brachial index. Sci Rep 2020; 10(1): 17076.
[http://dx.doi.org/10.1038/s41598-020-74267-7] [PMID: 33051540]
[48]
Boswijk E, Sanders KJC, Broeders EPM, et al. TSH suppression aggravates arterial inflammation — an 18F-FDG PET study in thyroid carcinoma patients. Eur J Nucl Med Mol Imaging 2019; 46(7): 1428.
[49]
Dörr M, Robinson DM, Wallaschofski H, et al. Low serum thyrotropin is associated with high plasma fibrinogen. J Clin Endocrinol Metab 2006; 91(2): 530-4.
[http://dx.doi.org/10.1210/jc.2005-1786] [PMID: 16303831]
[50]
Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: Subclinical hyperthyroidism increases plasma factor X activity. Clin Endocrinol 2006; 64(3): 323-9.
[http://dx.doi.org/10.1111/j.1365-2265.2006.02464.x] [PMID: 16487444]
[51]
Homoncik M, Gessl A, Ferlitsch A, Jilma B, Vierhapper H. Altered platelet plug formation in hyperthyroidism and hypothyroidism. J Clin Endocrinol Metab 2007; 92(8): 3006-12.
[http://dx.doi.org/10.1210/jc.2006-2644] [PMID: 17488803]
[52]
Takawale A, Aguilar M, Bouchrit Y, Hiram R. Mechanisms and management of thyroid disease and atrial fibrillation: Impact of atrial electrical remodeling and cardiac fibrosis. Cells 2022; 11(24): 4047.
[http://dx.doi.org/10.3390/cells11244047] [PMID: 36552815]
[53]
Goldstein SA, Green J, Huber K, et al. Characteristics and outcomes of atrial fibrillation in patients with thyroid disease (from the ARISTOTLE Trial). Am J Cardiol 2019; 124(9): 1406-12.
[http://dx.doi.org/10.1016/j.amjcard.2019.07.046] [PMID: 31474328]
[54]
Poredoš P, Schernthaner GH, Blinc A, et al. Endocrine disorders and peripheral arterial disease: A series of reviews. Curr Vasc Pharmacol 2023; 21(3): 147-8.
[http://dx.doi.org/10.2174/1570161121666230516141319] [PMID: 37194233]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy